Beginning in mid-February 2008, the 1997-2007 online version of the Science Watch® newsletter, ESI-Topics.com, and in-cites.com, will all be featured together on the redesigned ScienceWatch.com. All previous content from the three sites will be permanently archived, and remain accessible from any existing bookmarks to the archived pages. No new content will be added to this site. Updates and new content (updated biweekly) are available at ScienceWatch.com now.

Emerging Research Fronts Comments

Return to menu of Emerging Research Fronts

ESI Special Topics, June 2005
Citing URL: http://www.esi-topics.com/erf/2005/june05-DavidPoyner.html

From •>>June 2005

David Poyner answers a few questions about this month's emerging research front in field of Pharmacology & Toxicology:

Pharmacology & Toxicology
Article: International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors
Authors: Poyner, DR;Sexton, PM;Marshall, I;Smith, DM;Quirion, R;Born, W;Muff, R;Fischer, JA;Foord, SM
Journal: PHARMACOL REV, 54: (2) 233-246, JUN 2002
Addresses:
Aston Univ, Inst Pharmaceut Sci, Birmingham B4 7ET, W Midlands, England.
Aston Univ, Inst Pharmaceut Sci, Birmingham B4 7ET, W Midlands, England.
Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3052, Australia.
Univ Coll London, Dept Pharmacol, London, England.
AstraZeneca Pharmaceut, Alderley Edge, Cheshire, England.
McGill Univ, Douglas Hosp Res Ctr, Verdun, PQ, Canada.
McGill Univ, Dept Psychiat, Verdun, PQ, Canada.
Univ Zurich, Klin Balgrist, Dept Orthoped Surg, Res Lab Calcium Metab, Zurich, Switzerland.
Univ Zurich, Klin Balgrist, Dept Med, Res Lab Calcium Metab, Zurich, Switzerland.
GlaxoSmithKline, Med Res Ctr, Stevenage, Herts, England.


ST:  Why do you think your paper is highly cited?

 

“This article reviewed the field and considered how many types of receptor we should expect to find as a result of this mechanism and what properties these should have. By proposing a standard nomenclature, it will make it easier for scientists to compare results. ”

The paper is a review article sponsored by IUPHAR (International Union of Pharmacology) that provides guidelines as to the nomenclature of the four types of receptors. The nature of these receptors is highly unusual; they are G-protein coupled receptors which require the expression of accessory proteins—Receptor Activity-modifying Proteins (RAMPs)—and thus the field is of some general interest. Furthermore, the detailed pharmacology is controversial. By bringing together many of the main workers in the field we were able to produce a balanced account of the subject which suggested some explanations for these pharmacological puzzles. Anyone working on these receptors is likely to cite this article to verify the usage of nomenclature and abbreviations.

ST:  Does it describe a new discovery or new methodology that's useful to others?

As this was a review article, it primarily considered the significance of novel data that had already been published. However, it also suggested new ways of thinking about the pharmacology of these peptides.

ST:  Could you summarize the significance of your paper in layman's terms?

Calcitonin (CT), calcitonin gene-related peptide (CGRP), amylin, and adrenomedullin are peptides produced by the body as hormones or neurotransmitters. They have many effects, from bone growth to changes in blood pressure, and so are medically very important. They are related to each other and they produce their effects by interacting with proteins on the surface of cells; these proteins are called receptors. The receptors are very unusual in that they need extra proteins called RAMPs to function—it is possible to turn a CGRP receptor into an adrenomedullin receptor or a calcitonin receptor into an amylin receptor by switching the type of RAMP. This article reviewed the field and considered how many types of receptors we should expect to find as a result of this mechanism and what properties these receptors should have. By proposing a standard nomenclature, it will make it easier for scientists to compare results.

ST:  How did you become involved in this research?

The article was very much a joint effort. It was originated by IUPHAR and the team to write it was organized by Steve Foord. Patrick Sexton, Jan Fisher, Walter Born, and Roman Muff wrote the section on calcitonin and amylin; Dave Smith produced the section on adrenomedullin; Remi Quirion, Steve Foord, Ian Marshall, and I did the section on CGRP. Steve also did produce some background information on RAMPs as his lab had discovered these just a few years before we wrote the article.End

David Poyner
Senior Lecturer
School of Life and Health Sciences
Aston University
Birmingham, UK

Return to Emerging Research Fronts | Return to Special Topics main menu
 

ESI Special Topics, June 2005
Citing URL: http://www.esi-topics.com/erf/2005/june05-DavidPoyner.html

ScienceWatch.com - Tracking Trends and Perfomance in Basic Research
Go to the new ScienceWatch.com

Write to the Webmaster with questions/comments. Terms of Usage.
The Research Services Group of Thomson Scientific |
(c) 2008 The Thomson Corporation.